The Effects of Traditional Chinese Medicine-Associated Complementary and Alternative Medicine on Women with Polycystic Ovary Syndrome - PubMed (original) (raw)

Review

. 2021 Feb 26:2021:6619597.

doi: 10.1155/2021/6619597. eCollection 2021.

Affiliations

Review

The Effects of Traditional Chinese Medicine-Associated Complementary and Alternative Medicine on Women with Polycystic Ovary Syndrome

Wenjuan Shen et al. Evid Based Complement Alternat Med. 2021.

Abstract

Polycystic ovary syndrome (PCOS) is a touchy clinical and public health problem worldwide, which adversely affects women's health and health-related comorbidities for lifetime, and represents a tremendous burden for both the family of the patient and for society. According to the diagnostic criteria used and the population studied, the prevalence rate of PCOS is between 6% and 21%. However, current conventional modern medicines for PCOS are only moderately effective at controlling the signs and symptoms, while they are not thoroughly able to prevent complications. Therefore, many patients have turned to complementary and alternative medical (CAM) treatments. CAM use is wide spread among patients with PCOS, and more than 70% of patients use CAM at one point during their diseases. The patients' primary motivations include dissatisfaction with available medications, perceive higher risk of drug side effects and crushing health burden and economic costs, desire for symptom relief, pursuit of shortening the course of disease, and the belief that CAM therapy is in accordance with the patients' values and beliefs. At present, several CAM methods have been used in women with PCOS, which has achieved obvious effects. However, biologically plausible mechanisms of the action of traditional Chinese medicine- (TCM-) associated CAM for PCOS have not been systematically reviewed. This review briefly summarizes the current progress of the impact of herbal medicine on the outcomes of PCOS and introduces the mechanisms.

Copyright © 2021 Wenjuan Shen et al.

PubMed Disclaimer

Conflict of interest statement

The authors declare that there are no conflicts of interest in this work.

Similar articles

Cited by

References

    1. Joham A. E., Teede H. J., Ranasinha S., Zoungas S., Boyle J. Prevalence of infertility and use of fertility treatment in women with polycystic ovary syndrome: data from a large community-based cohort study. Journal of Women’s Health. 2015;24(4):299–307. doi: 10.1089/jwh.2014.5000. - DOI - PubMed
    1. Boyle H. J., Misso M. L., Costello M. F., et al. Recommendations from the international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Fertility and Sterility. 2018;110(3):364–379. doi: 10.1016/j.fertnstert.2018.05.004. - DOI - PMC - PubMed
    1. Norman G., Massaro M. G., Di Sabatino A., Cappelli V., De Leo V. Therapeutic approach for metabolic disorders and infertility in women with PCOS. Gynecological Endocrinology. 2018;34(1):4–9. doi: 10.1080/09513590.2017.1370644. - DOI - PubMed
    1. Dumesic D. A., Oberfield S. E., Stener-Victorin E., Marshall J. C., Laven J. S., Legro R. S. Scientific statement on the diagnostic criteria, epidemiology, pathophysiology, and molecular genetics of polycystic ovary syndrome. Endocrine Reviews. 2015;36(5):487–525. doi: 10.1210/er.2015-1018. - DOI - PMC - PubMed
    1. Legro T., Hardiman P. J., Petersen I., Baio G. Incidence and prevalence of diabetes and cost of illness analysis of polycystic ovary syndrome: a Bayesian modelling study. Human Reproduction. 2018;33(7):1299–1306. doi: 10.1093/humrep/dey093. - DOI - PubMed

Publication types

LinkOut - more resources